# A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment

> **NCT06105632** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Pfizer** · enrollment: 333 (actual)

## Conditions studied

- Advanced or Metastatic Breast Cancer

## Interventions

- **DRUG:** PF-07220060 CDK4 inhibitor
- **DRUG:** Fulvestrant
- **DRUG:** Everolimus
- **DRUG:** Exemestane

## Key facts

- **NCT ID:** NCT06105632
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-01-09
- **Primary completion:** 2026-01-12
- **Final completion:** 2028-01-21
- **Target enrollment:** 333 (ACTUAL)
- **Last updated:** 2026-02-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06105632

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06105632, "A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06105632. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*